Telisotuzumab adizutecan (ABBV-400; Temab-A), a c-Met protein–targeting antibody-drug conjugate (ADC), in patients (pts) with advanced <i>EGFR</i> -mutated (MT) non-squamous (NSQ) non-small cell lung cancer (NSCLC): Results from a phase 1 study.

❌ 缺失

Telisotuzumab adizutecan（ABBV-400；Temab-A），一种靶向c-Met蛋白的抗体-药物结合物（ADC），在晚期EGFR突变（MT）非鳞状（NSQ）非小细胞肺癌（NSCLC）患者中的研究结果：一期研究结果

作者 David Ross Camidge; Judith Raimbourg; Yun-Gyoo Lee; Maria J. de Miguel; Antoine Hollebecque; Tae Min Kim; Yutaka Fujiwara; François Ghiringhelli; Dae Ho Lee; Jonathan W. Goldman; Mor Moskovitz; Takako Eguchi Nakajima; David Vincente Baz; Zoe Hunter; Michael Charles Burns; Martha Elizabeth Blaney; Rui Li; Tony Navas; Theodore S. Jennaro; David Sommerhalder 期刊 Journal of Clinical Oncology 发表日期 2025 卷/期/页码 Vol. 43(16_suppl) ISSN 0732-183X DOI 10.1200/JCO.2025.43.16_suppl.8512 类型原创研究 (Original Research)